Jaguar Health, Inc. — fact timeline

Jaguar Health, Inc. amended loan of original principal amount of $6,220,812.50 with Streeterville Capital, LLC maturing October 1, 2026.

“On June 17, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 4”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date. Pursuant to the 2021 Note Amendment No. 4, the maturity date of the 2021 Note is extended from July 1, 2026 to October 1, 2026.”

Jaguar Health, Inc. amended debt of original principal amount of $12 million with Streeterville Capital, LLC.

“On June 17, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million dated August 24, 2022, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which Section 2.2 of the Streeterville 2022 Royalty Interest was deleted and replaced in its entirety such that initiation of monthly payments shall be extended from July 1, 2026 to October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Streeterville is entitled to for such month pursuant to Section 2.1 of the Streeterville 2022 Royalty Interest.”

Jaguar Health, Inc. amended debt of original principal amount of $12 million with Uptown Capital, LLC.

“On June 17, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), pursuant to which Section 2.2 of the Uptown 2020 Royalty Interest was deleted and replaced in its entirety such that, beginning on October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Uptown is entitled to for such month pursuant to Section 2.1 of the Uptown 2020 Royalty Interest.”

Jaguar Health, Inc. entered into Second Exchange Agreement with Streeterville Capital, LLC ("Streeterville") (effective 2026-06-17).

“On June 17, 2026, the Company entered into another privately negotiated exchange agreement with Streeterville (the “Second Exchange Agreement”), pursuant to which the Company issued 36,796 shares (the “Second Exchange Shares”) of Common Stock to Streeterville in exchange for an aggregate of 3.4 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Second Exchanged Preferred Shares”), which when combined with the First Exchange Shares resulted in the aggregate issuance by the Company of more than 5% of the Company’s issued and outstanding shares of Common Stock, as last reported in the Company’s Quarterly Report on Form 10-Q filed on May 20, 2026.”

Jaguar Health, Inc. entered into First Exchange Agreement with Streeterville Capital, LLC ("Streeterville") (effective 2026-06-09).

“On June 9, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 34,798 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), to Streeterville in exchange for an aggregate of 3.8 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).”

Jaguar Health, Inc. amended 2021 Note Amendment No. 4 with Streeterville Capital, LLC (as lender, together with Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. as borrower) (effective 2026-06-17).

“On June 17, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 4”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.”

Jaguar Health, Inc. amended Streeterville 2022 Royalty Interest Global Amendment No. 5 with Streeterville Capital, LLC ("Streeterville") (effective 2026-06-17).

“On June 17, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million dated August 24, 2022, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which Section 2.2 of the Streeterville 2022 Royalty Interest was deleted and replaced in its entirety such that initiation of monthly payments shall be extended from July 1, 2026 to October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Streeterville is entitled to for such month pursuant to Section 2.1 of the Streeterville 2022 Royalty Interest.”

Jaguar Health, Inc. amended Uptown 2020 Royalty Interest Global Amendment No. 5 with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; "Uptown") (effective 2026-06-17).

“On June 17, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), pursuant to which Section 2.2 of the Uptown 2020 Royalty Interest was deleted and replaced in its entirety such that, beginning on October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Uptown is entitled to for such month pursuant to Section 2.1 of the Uptown 2020 Royalty Interest.”

Jaguar Health, Inc. issued common stock to Institutional Investor.

“In consideration for the Institutional Investor’s execution and delivery of the ELOC Agreement, the Company agreed to issue to the Institutional Investor on the effective date of the ELOC Registration Statement (as defined hereunder) $800,000 worth of the Company’s Common Stock, valued at the VWAP Purchase Price as of such effective date (the “Commitment Shares”).”

Jaguar Health, Inc.: Filed Series P Certificate of Designation with Delaware Secretary of State on June 8, 2026, effective upon filing, authorizing up to 300 shares of Series P Preferred Stock with specific dividend, voting, and liquidation preferences (effective 2026-06-08).

“The preferences, rights, limitations and other matters relating to the Series P Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on June 8, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing. The Certificate of Designation authorizes the Company to issue up to 300 of its 4,475,074 authorized shares of preferred stock as Series P Preferred Stock.”

Jaguar Health, Inc. entered into common stock purchase agreement with an accredited investor valued at up to an aggregate of $40 million (effective 2026-06-09).

“On June 9, 2026, Jaguar Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “ELOC Agreement”) with an accredited investor (the “Institutional Investor”), which provides that, upon the terms and subject to the conditions set forth therein, the Institutional Investor is committed to purchase up to an aggregate of $40 million of shares of Common Stock.”

Jaguar Health, Inc. shareholders approved Grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposals 3 and 4. at the 2026-06-08 meeting.

“Proposal to approve a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposals 3 and 4, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 3,928,027 258,049 21,953 2,961,123”

Jaguar Health, Inc. shareholders approved Approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of more than 19.99% of the Company’s issued and outstanding shares of Common Stock to C/M Capital pursuant to a securities purchase agreement to be entered into within 90 days after the date of the Annual Meeting (the "Preferred Stock Pu at the 2026-06-08 meeting.

“Proposal to approve, pursuant to Rule 5635(d), the issuance of more than 19.99% of the Company’s issued and outstanding shares of Common Stock to C/M Capital pursuant to a securities purchase agreement to be entered between the Company and C/M Capital within 90 days after the date of the Annual Meeting (the “Preferred Stock Purchase Agreement”), including shares of Common Stock issuable upon redemption of shares of a new series of preferred stock of the Company, par value $0.0001 per share, to be designated as Series P Non-Convertible Preferred Stock (the “Series P Preferred Stock”), to be issued and sold pursuant to the Preferred Stock Purchase Agreement, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 3,846,847 336,712 24,470 2,961,123”

Jaguar Health, Inc. shareholders approved Approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of more than 19.99% of the Company’s issued and outstanding shares of Common Stock to C/M Capital Master Fund, LP (and its affiliates) pursuant to a securities purchase agreement to be entered into within 90 days after the date of the An at the 2026-06-08 meeting.

“Proposal to approve, pursuant to Nasdaq Listing Rule 5635(d) (Rule 5635(d)), the issuance of more than 19.99% of the Company’s issued and outstanding shares of Common Stock to C/M Capital Master Fund, LP (and its affiliates), an accredited investor (“C/M Capital”), pursuant to a securities purchase agreement to be entered into between the Company and C/M Capital within 90 days after the date of the Annual Meeting (the “ELOC Agreement”), was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 3,891,273 291,441 25,315 2,961,123”

Jaguar Health, Inc. shareholders approved Ratify the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-08 meeting.

“Proposal to ratify the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 6,898,326 238,443 32,383 0”

Jaguar Health, Inc. shareholders approved Election of one Class II director to the Company's board of directors to hold office for a three-year term until the annual meeting of stockholders in 2029 and until such director's successor is elected and qualified. at the 2026-06-08 meeting.

“Proposal to elect one Class II director to the Company’s board of directors to hold office for a three-year term until the annual meeting of stockholders in 2029 and until such director’s successor is elected and qualified. The votes regarding this proposal were as follows: For Withheld Broker Non- Votes John Micek III 3,967,085 240,944 2,961,123”

Jaguar Health, Inc. entered into Second Exchange Agreement with Streeterville Capital, LLC (effective 2026-06-01).

“On June 1, 2026, the Company entered into another privately negotiated exchange agreement with Streeterville (the “Second Exchange Agreement”), pursuant to which the Company issued 32,710 shares (the “Second Exchange Shares”) of Common Stock to Streeterville in exchange for an aggregate of 4.2 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Second Exchanged Preferred Shares”).”

Jaguar Health, Inc. entered into First Exchange Agreement with Streeterville Capital, LLC (effective 2026-05-26).

“On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).”

Jaguar Health, Inc. entered into Exchange Agreements with Streeterville Capital, LLC valued at 54,222 shares of common stock in exchange for 7.96 shares of Series Q Preferred Stock (effective 2026-05-21).

“On May 21, 2026, the Company entered into two privately negotiated exchange agreements with Streeterville (the “Exchange Agreements”), pursuant to which the Company issued an aggregate of 54,222 shares of the Company’s common stock, par value $0.0001 (the “Common Exchange Shares”) to Streeterville in exchange for an aggregate of 7.96 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Exchanged Preferred Shares”).”

Jaguar Health, Inc. reported first quarter 2026 results: revenue $20,272, net income $(7,015), EPS $(13.60).

“per share amounts) 2026 2025 $ change % change License and grant revenue, net $ 19,068 $ 43 19,025 44244 % Product revenue, net 1,204 2,171 (967 ) -45 % Total revenue, net $ 20,272 $ 2,214 18,058 816 % Income (loss) from operations $ 10,182 $ (9,421 ) 19,602 208 % Net loss attributable to common stockholders $ (7,015 ) $ (10,464 ) 3,449 33 % Net loss per”

Jaguar Health, Inc. entered into Second Streeterville Series Q Exchange Agreement with Streeterville Capital, LLC valued at $6,500,000 reduction in the outstanding balance (effective 2026-05-19).

“and (ii) a privately negotiated exchange agreement (the "Second Streeterville Series Q Exchange Agreement"; together with the Uptown Series Q Exchange Agreement and the First Streeterville Series Q Exchange Agreement, collectively, the "CVP Exchange Agreements") also with Streeterville, pursuant to which the Company issued 260 shares of Series Q Preferred Stock to Streeterville in exchange for an additional $6,500,000 reduction in the outstanding balance of the August 2022 Royalty Interest.”

Jaguar Health, Inc. entered into First Streeterville Series Q Exchange Agreement with Streeterville Capital, LLC valued at $3,700,000 reduction in the outstanding balance (effective 2026-05-19).

“On May 19, 2026, the Company entered into (i) a privately negotiated exchange agreement (the "First Streeterville Series Q Exchange Agreement") with Streeterville, pursuant to which the Company issued 148 shares of Series Q Preferred Stock to Streeterville in exchange for a $3,700,000 reduction in the outstanding balance of the August 2022 Royalty Interest”

Jaguar Health, Inc. entered into Uptown Series Q Exchange Agreement with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC) valued at $12,500,000 reduction in the outstanding balance (effective 2026-05-19).

“On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the "Uptown Series Q Exchange Agreement") with Uptown. Pursuant to the Uptown Series Q Exchange Agreement, the Company issued 500 shares of Series Q Perpetual Preferred Stock (the "Series Q Preferred Stock") to Uptown in exchange for a $12,500,000 reduction in the outstanding balance of the December 2020 Royalty Interest.”

Jaguar Health, Inc. amended debt of $12 million with Streeterville Capital, LLC.

“22, 2020, Jaguar Health, Inc. (the “Company”) sold to Uptown Capital, LLC(f/k/a Irving Park Capital, LLC) (“Uptown”) a royalty interest in the original principal amount of $12 million (as amended, the “December 2020 Royalty Interest”). On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the “Uptown Series Q Exchange Agreement”)”

Jaguar Health, Inc. amended debt of $12 million with Uptown Capital, LLC.

“22, 2020, Jaguar Health, Inc. (the “Company”) sold to Uptown Capital, LLC(f/k/a Irving Park Capital, LLC) (“Uptown”) a royalty interest in the original principal amount of $12 million (as amended, the “December 2020 Royalty Interest”). On May 19, 2026, the Company entered into a privately negotiated exchange agreement (the “Uptown Series Q Exchange Agreement”)”

Jaguar Health, Inc.: Filed Certificate of Designation for Series Q Preferred Stock, establishing preferences, rights, and limitations (effective 2026-05-19).

“The preferences, rights, limitations and other matters relating to the Series Q Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on May 19, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing.”

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4), 5810(d), 5810(c)(3)(A)).

“May 1, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying th”

Jaguar Health, Inc. issued common stock.

“To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.”

Jaguar Health, Inc.: Filed Eleventh Amendment to Third Amended and Restated Certificate of Incorporation to effect a 1-for-35 reverse stock split (effective 2026-04-30).

“the Company filed the Eleventh Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eleventh Amendment at 12:01 am Eastern Time on April 30, 2026”

Jaguar Health, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).

“April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su”

Jaguar Health, Inc.: Tenth Amendment to the Certificate of Incorporation to increase authorized shares of voting common stock from 298,000,000 to 500,000,000 and total authorized shares from 352,475,074 to 554,475,074 (effective 2026-04-20).

“item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. At a special meeting of stockholders of Jaguar Health, Inc. (the “Company”) held on April 20, 2026 (the “Special Meeting”), the Company’s stockholders approved an amendment (the “Tenth Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation (the “COI”) to effect an increase in the number of authorized shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”), from 298,000,000 shares to 500,000,000 shares and a corresponding increase in the total number of shares the Company is authorized to issue from 352,475,074 shares to 554,475,074 shares (the “Authorized Share Increase”).”

Jaguar Health, Inc. reported year ended December 31, 2025 results: revenue $11.5 million, net income $53.6 million net loss, EPS ($24.27) per share.

“the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million. • In 2025, approximately $11.2 million out of the Company’s total net revenue of $11.5 million was generated by sales of Mytesi and Canalevia-CA1. Under the terms of the license agreement Jaguar entered with Future Pak (“FP”) in January 2026, FP will be responsible for all”

Jaguar Health, Inc. terminated Warrant Termination Agreement with Uptown Capital, LLC, Streeterville Capital, LLC, Iliad Research and Trading, L.P. (effective 2026-03-06).

“On March 6, 2026, the Company entered into a warrant termination agreement (the “Warrant Termination Agreement”) with Uptown, Streeterville, and Iliad Research and Trading, L.P. (“Iliad”; and together with Uptown and Streeterville, collectively the “Investors”), pursuant to which, warrants exercisable into an aggregate of 48,211 shares of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”) previously issued by the Company to the Investors would be terminated.”

Jaguar Health, Inc. amended 2025 Note Amendment with Streeterville Capital, LLC valued at $7,048,021.86 (effective 2026-03-06).

“On March 6, 2026, the Company also entered into an amendment (the “2025 Note Amendment”) with Streeterville to the secured promissory note in the original principal amount of $10,810,000.00 (the “2025 Note”) issued by the Company to Streeterville on November 12, 2025 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.”

Jaguar Health, Inc. amended 2021 Note Amendment No. 3 with Streeterville Capital, LLC valued at $6,596,304.11 (effective 2026-03-06).

“On March 6, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 3”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.”

Jaguar Health, Inc. amended Streeterville 2022 Royalty Interest Global Amendment No. 4 with Streeterville Capital, LLC valued at $12,428,782.20 (effective 2026-03-06).

“On March 6, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 4”) to the royalty interest in the original principal amount of $12 million, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which, (i) the starting date for the Company to make the monthly Royalty Payment under the Streeterville 2022 Royalty Interest would be postponed from April 1, 2026 to July 1, 2026, and (ii) the Royalty Repayment Amount (as defined in the Streeterville 2022 Royalty Interest) would be reduced by ten percent.”

Jaguar Health, Inc. amended Uptown 2020 Royalty Interest Global Amendment No. 4 with Uptown Capital, LLC valued at $11,125,282.54 (effective 2026-03-06).

“On March 6, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 4”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, pursuant to which, (i) the starting date for the Company to make the monthly Royalty Payment under the Uptown 2020 Royalty Interest would be postponed from April 1, 2026 to July 1, 2026, and (ii) the Royalty Repayment Amount (as defined in the Uptown 2020 Royalty Interest) would be reduced by ten percent.”

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“March 5, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the bid price for the Company’s common stock for the previous 30 consecutive business days had closed below the minimum $1.00 per share, the Company was no longer in compliance with the requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Further, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)”

Jaguar Health, Inc.: Filed Certificate of Designation for Series O Convertible Preferred Stock (effective 2026-03-02).

“on March 2, 2026 the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series O Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, to designate 1,557,000 shares of the Company’s preferred stock, par value $0.0001 per share, as Series O Convertible Preferred Stock”

Jaguar Health, Inc. issued 2,870,503 shares of warrant to Iliad Research and Trading, L.P. for 87.78 shares of Series M Preferred Stock.

“pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the "Fifth Pre-Funded Warrant") to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.”

Jaguar Health, Inc. issued 3,249,908 shares of warrant to Streeterville Capital, LLC for 99.3822 shares of Series L Preferred Stock.

“pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the "Fourth Pre-Funded Warrant") to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.”

Jaguar Health, Inc. issued 719,424 shares of warrant to Iliad Research and Trading, L.P. for 22 shares of Series L Preferred Stock.

“pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the "Third Pre-Funded Warrant") to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.”

Jaguar Health, Inc. issued 1,111,837 shares of warrant to Streeterville Capital, LLC for $850,000 reduction in the outstanding balance of the August 2022 Royalty Interest.

“with Streeterville. Pursuant to this agreement, the Company issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock (the "Second Pre-Funded Warrant") to Streeterville in exchange for a $850,000 reduction in the outstanding balance of the August 2022 Royalty Interest.”

Jaguar Health, Inc. issued 1,553,844 shares of warrant to Iliad Research and Trading, L.P. for $1,187,914.07 reduction in the outstanding balance of the October 2020 Royalty Interest.

“with Iliad. Pursuant to this agreement, the Company issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock (the "First Pre-Funded Warrant") to Iliad in exchange for a $1,187,914.07 reduction in the outstanding balance of the October 2020 Royalty Interest.”

Jaguar Health, Inc. entered into Streeterville Series M Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock (the “Sixth Pre-Funded Warrant”) to Streeterville in exchange for 69.44 shares of Series M Preferred Stock held by Streeterville.”

Jaguar Health, Inc. entered into Iliad Series M Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the “Fifth Pre-Funded Warrant”) to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.”

Jaguar Health, Inc. entered into Streeterville Series L Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the “Fourth Pre-Funded Warrant”) to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.”

Jaguar Health, Inc. entered into Iliad Series L Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the “Third Pre-Funded Warrant”) to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.”

Jaguar Health, Inc. entered into Streeterville Royalty Interest Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Streeterville Royalty Interest Exchange Agreement”) with Streeterville.”

Jaguar Health, Inc. entered into Iliad Royalty Interest Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex (effective 2026-01-16).

“On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Iliad Royalty Interest Exchange Agreement”) with Iliad.”